Global Blood Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
Global Blood Therapeutics, Inc.‘s stocks are currently a part of 197 hedge funds’ portfolios, which represents 100% of the total amount of its stocks outstanding. This makes up a total of 87.66M shares of Global Blood Therapeutics, Inc.. Compared to the previous quarter, the number grew by 34.16% or 22.32M shares more. As for the holding position changes, 38.58% (76) of current hedge fund investors increased the number of shares held, 30.46% (60) of current holders sold a part of the shares held, and 14.72% (29) closed the holdings completely. 31 hedge funds are new holders of Global Blood Therapeutics, Inc. stock in Q1 2022, it is 15.74% of total holders.
Hedge funds holding Global Blood Therapeutics (Q2 2017 – Q1 2022)
| Q2 2017 | 134 |
|---|---|
| Q3 2017 | 136 |
| Q4 2017 | 158 |
| Q1 2018 | 174 |
| Q2 2018 | 196 |
| Q3 2018 | 183 |
| Q4 2018 | 188 |
| Q1 2019 | 197 |
| Q2 2019 | 219 |
| Q3 2019 | 203 |
| Q4 2019 | 228 |
| Q1 2020 | 214 |
| Q2 2020 | 246 |
| Q3 2020 | 221 |
| Q4 2020 | 219 |
| Q1 2021 | 207 |
| Q2 2021 | 187 |
| Q3 2021 | 181 |
| Q4 2021 | 200 |
| Q1 2022 | 197 |
Hedge funds changes in Global Blood Therapeutics positions (Q2 2017 – Q1 2022)
| Q2 2017 | 37 | 64 | 25 | 19 | -11 |
|---|---|---|---|---|---|
| Q3 2017 | 24 | 50 | 40 | 19 | 3 |
| Q4 2017 | 48 | 49 | 51 | 26 | -16 |
| Q1 2018 | 45 | 63 | 56 | 27 | -17 |
| Q2 2018 | 44 | 87 | 48 | 21 | -4 |
| Q3 2018 | 26 | 72 | 60 | 39 | -14 |
| Q4 2018 | 42 | 66 | 62 | 33 | -15 |
| Q1 2019 | 27 | 65 | 72 | 20 | 13 |
| Q2 2019 | 49 | 89 | 47 | 24 | 10 |
| Q3 2019 | 27 | 91 | 50 | 40 | -5 |
| Q4 2019 | 60 | 77 | 61 | 26 | 4 |
| Q1 2020 | 33 | 78 | 70 | 43 | -10 |
| Q2 2020 | 56 | 78 | 81 | 24 | 7 |
| Q3 2020 | 28 | 90 | 75 | 51 | -23 |
| Q4 2020 | 56 | 83 | 59 | 58 | -37 |
| Q1 2021 | 26 | 62 | 95 | 36 | -12 |
| Q2 2021 | 22 | 80 | 55 | 40 | -10 |
| Q3 2021 | 27 | 75 | 48 | 31 | 0 |
| Q4 2021 | 47 | 62 | 64 | 28 | -1 |
| Q1 2022 | 31 | 76 | 60 | 29 | 1 |
Hedge funds changes in Global Blood Therapeutics stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 14,001,000 | 9,273,000 |
|---|---|---|
| Q3 2017 | 14,851,000 | 4,435,000 |
| Q4 2017 | 49,548,000 | 29,318,000 |
| Q1 2018 | 56,265,000 | 32,248,000 |
| Q2 2018 | 10,179,676,000 | 87,205,000 |
| Q3 2018 | 74,979,000 | 25,188,000 |
| Q4 2018 | 77,408,000 | 23,223,000 |
| Q1 2019 | 83,137,000 | 30,166,000 |
| Q2 2019 | 72,603,000 | 73,283,000 |
| Q3 2019 | 58,897,000 | 32,054,000 |
| Q4 2019 | 174,222,000 | 64,015,000 |
| Q1 2020 | 31,761,000 | 35,792,000 |
| Q2 2020 | 52,773,000 | 49,995,000 |
| Q3 2020 | 27,997,000 | 30,592,000 |
| Q4 2020 | 43,137,000 | 56,968,000 |
| Q1 2021 | 20,742,000 | 22,591,000 |
| Q2 2021 | 63,279,000 | 9,804,000 |
| Q3 2021 | 44,805,000 | 8,790,000 |
| Q4 2021 | 13,153,000 | 8,900,000 |
| Q1 2022 | 13,942,000 | 13,963,000 |